FDA Rethinks Ultra-Rare Drug Approval

Precision genetic medicine has advanced to the point where therapies can be designed to target a single pathogenic mutation in a handful of patients. Genome editing tools and RNA-based therapies now make it possible to intervene directly at the molecular root of disease. For some ultra-rare conditions, such therapies represent the only plausible treatment pathway.